Nurix Therapeutics, Inc. 8-K

What Happened
Nurix Therapeutics, Inc. (NRIX) filed a Form 8-K on January 28, 2026 under Item 2.02 to announce its financial results for the fiscal quarter and year ended November 30, 2025. The company issued a press release with those results, which is furnished as Exhibit 99.1 and incorporated by reference in the filing. The 8-K was signed by President and CEO Arthur T. Sands, M.D., Ph.D.

Key Details

• Filing date: January 28, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: fiscal quarter and fiscal year ended November 30, 2025.
• Press release announcing results provided as Exhibit 99.1 (and Inline XBRL cover page as Exhibit 104).
• 8-K signed by Arthur T. Sands, President and Chief Executive Officer.

Why It Matters
This filing notifies investors that Nurix has released its latest earnings information for the quarter and full fiscal year; those results can affect stock performance and assessments of the company’s revenue, expenses, cash runway and progress on programs. The 8-K itself does not include numeric financials in-line — investors should review the furnished press release (Exhibit 99.1) for detailed figures, trends and any management commentary or guidance.